SciELO - Scientific Electronic Library Online

Avena, Nicole M., P. Rada y B. G. Hoebel. 2008a. "Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake", Neurosci Biobehav Rev, vol. 32, pp. 20–39. [ Links ]

–––––––––– 2008b. "Underweight rats have enhanced dopamine release and blunted acetylcholine response in the nucleus accumbens while bingeing on sucrose", Neuroscience, vol. 156, pp. 865–871. [ Links ]

Bab, Itai, A. Zimmer, y E. Melamed. 2009. "Cannabinoids and the skeleton: from marijuana to reversal of bone loss", Ann Med, vol. 41, pp. 560–567. [ Links ]

Bahr, Ben A. et al. 2006. "Targeting the endocannabinoid system in treating brain disorders", Expert Opin Investig Drugs, vol. 15, pp. 351–365. [ Links ]

Ben Amar, M. 2006. "Cannabinoids in medicine: A review of their therapeutic potential". J Ethnopharmacol, vol. 105, pp. 1–25. [ Links ]

Benito, Cristina et al. 2007. "The endocannabinoid system and Alzheimer's disease". Mol Neurobiol, vol. 36, pp. 75–81. [ Links ]

Budney, Alan J. et al. 2007. "Marijuana dependence and its treatment", Addict Sci Clin Pract, vol. 4, pp. 4–16. [ Links ]

Burns, Tammy L. y J. R. Ineck. 2006. "Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain", Ann Pharmacother, vol. 40, pp. 251–260. [ Links ]

Burstein, Sumner H., y R. B. Zurier. 2009. "Cannabinoids, endocannabinoids, and related analogs in inflammation". AAPS J, vol. 11, pp. 109–19. [ Links ]

Cabral, Guy A., y A. Staab. 2005. "Effects on the immune system", Handb Exp Pharmacol, vol.168, pp. 385–423. [ Links ]

Christensen, Robin et al. 2007. "Efficacy and safety of the weight–loss drug rimonabant: a meta–analysis of randomised trials", Lancet, vol. 370, pp. 1706–1713. [ Links ]

Cooper, Ziva D., y M. Haney. 2008. "Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor", Addict Biol, vol. 13, pp. 188–195. [ Links ]

Correa, Fernando et al. 2005. "The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation", Mini Rev Med Chem, vol. 5, pp. 671–5. [ Links ]

Cota, Daniela et al. 2006. "Cannabinoids, opioids and eating behavior: the molecular face of hedonism?" Brain Res Rev, vol. vol. 51, pp. 85–107. [ Links ]

Cudaback, Eiron, y N. Stella. 2007. "Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue", Mol Neurobiol, vol. 36, pp. 36–44. [ Links ]

Devane, William A. et al. 1992. "Isolation and structure of a brain constituent that binds to the cannabinoid receptor", Science, vol. 258, pp. 1946–1949. [ Links ]

Downer, Eric J., y V. A. Campbell. 2010. "Phytocannabinoids, CNS cells and development: a dead issue?" Drug Alcohol Rev , vol. 29, pp.91–98. [ Links ]

Filbey, Francesca M. et al. 2009. "Marijuana craving in the brain", Proc Natl Acad Sci U S A, vol. 106, pp. 13016–13021. [ Links ]

Fride, Ester, T. Bregman y T. C. Kirkham. 2005. "Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood", Exp Biol Med (Maywood), vol. 230, pp. 225–234. [ Links ]

Garfield, Alastair S., y L. K. Heisler. 2009. "Pharmacological targeting of the serotonergic system for the treatment of obesity", J Physiol, vol. 587, pp. 49–60. [ Links ]

Gieringer, Dale H. 2006. "Origins of Cannabis Prohibition in California", Contemporary Drug Problems, Nueva York, EUA, Contemporary Drug Publications, vol. 26., pp. 1–36. [ Links ]

Grotenhermen, Franjo. 2005. "Cannabinoids", Curr Drug Targets CNS Neurol Disor, vol. 4, pp. 507–530. [ Links ]

Guzman, Manuel. 2003. "Cannabinoids: potential anticancer agents", Nat Rev Cancer, vol. 3, pp. 745–755. [ Links ]

Hall, Wayne, y L. Degenhardt. 2009. "Adverse health effects of non–medical cannabis use", Lancet, vol. 374, pp. 1383–1391. [ Links ]

Hoffmann, Diane E., y E. Weber. 2010. "Medical marijuana and the law", N Engl J Med, vol. 362, pp. 1453–1457. [ Links ]

Joffe, Alain, y W. S. Yancy. 2004. "Legalization of marijuana: potential impact on youth". Pediatrics, vol. 113, pp. e632–8. [ Links ]

Jourdan, Tony, et al. 2010. "CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet–induced obese mice", Diabetes, vol. 59, pp. 926–34. [ Links ]

Klein, Thomas W. 2005. "Cannabinoid–based drugs as anti–inflammatory therapeutics", Nat Rev Immunol, vol. 5, pp. 400–11. [ Links ]

Krishnan, Sarada, R. Cairns, y R. Howard. 2009. "Cannabinoids for the treatment of dementia", Cochrane Database Syst Rev, vol. 2, pp. D007204. [ Links ]

Lupica, Carl R., A. C. Riegel, y A. F. Hoffman. 2004. "Marijuana and cannabinoid regulation of brain reward circuits", Br J Pharmacol, vol. 143, (2):227–34. [ Links ]

Lynskey, Michael T., J. M. Vink, y D. I. Boomsma. 2006. "Early onset cannabis use and progression to other drug use in a sample of Dutch twins", Behav Genet, vol. 36, pp. 195–200. [ Links ]

MacCoun, Robert, y P. Reuter. 1997. "Interpreting Dutch cannabis policy: reasoning by analogy in the legalization debate", Science, vol. 278, pp. 47–52. [ Links ]

Machado Rocha, Francisco C. et al. 2008. "Therapeutic use of Cannabis sativa on chemotherapy–induced nausea and vomiting among cancer patients: systematic review and metaanalysis", Eur J Cancer Care (Engl), vol. 17, pp. 431–443. [ Links ]

Malfitano, Anna M., G. Matarese, y M. Bifulco. 2005. "From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases", Curr Drug Targets CNS Neurol Disord, vol. 4, pp. 667–675. [ Links ]

Marshall, Eliot. 1988. "Drug wars: legalization gets a hearing", Science, vol. 241, pp. 1157–1159. [ Links ]

Martin, Billy R., L. J. Sim–Selley, y D. E. Selley. 2004. "Signaling pathways involved in the development of cannabinoid tolerance", Trends Pharmacol Sci, vol. 25, pp. 325–330. [ Links ]

Pertwee, Roger G. 2005. "Pharmacological actions of cannabinoids", Handb Exp Pharmacol, vol. 168, pp. 1–51. [ Links ]

Pittler, Max H., y E. Ernst. 2008. "Complementary therapies for neuropathic and neuralgic pain: systematic review", Clin J Pain, vol. 24, pp. 731–733. [ Links ]

Reece, Albert S. 2009. "Chronic toxicology of cannabis", Clin Toxicol (Phila), vol. 47, pp. 517–524. [ Links ]

Rothman, Richard B., B. E. Blough, y M. H. Baumann. 2008. "Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction", Exp Clin Psychopharmacol, vol. 16, pp. 458–474. [ Links ]

Sarne, Yosef, y R. Mechoulam. 2005. "Cannabinoids: between neuroprotection and neurotoxicity", Curr Drug Targets CNS Neurol Disord, vol. 4, pp. 677–684. [ Links ]

Schweinsburg, Alecia D., S. A. Brown, y S. F. Tapert. 2008. "The influence of marijuana use on neurocognitive functioning in adolescents", Curr Drug Abuse Rev, vol. 1, pp.:99–111. [ Links ]

Smith, Adam M. et al. 2010. "Effects of marijuana on visuospatial working memory: an fMRI study in young adults", Psychopharmacology (Berl) vol. 210, pp. 429–438. [ Links ]

Smith, Paul F. 2010. "New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids", Ther Clin Risk Manag, vol. 6, pp. 59–63. [ Links ]

Velasco, Guillermo et al. 2007. "Cannabinoids and gliomas", Mol Neurobiol, vol. 36, pp. 60–67. [ Links ]

Ware, Mark A. et al. 2010. "The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial", Anesth Analg, vol. 110, pp. 604–610. [ Links ]